Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PRAX Stock Forecast 2026-2027
$298.46
Current Price
$8.28B
Market Cap
Buy 14
Hold 0
Sell 1
Wall St Analyst Ratings
Distance to PRAX Price Targets
+182.4%
To High Target of $843.00
+50.8%
To Median Target of $450.00
-68.2%
To Low Target of $95.00
PRAX Price Momentum
+3.5%
1 Week Change
+8.7%
1 Month Change
+324.9%
1 Year Change
+1.3%
Year-to-Date Change
-6.1%
From 52W High of $317.72
+1,017.8%
From 52W Low of $26.70
📊 TOP ANALYST CALLS
Did PRAX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Praxis is one of their latest high-conviction picks.
Latest PRAX Stock Price Targets & Analyst Predictions
Based on our analysis of 19 Wall Street analysts, PRAX has a bullish consensus with a median price target of $450.00 (ranging from $95.00 to $843.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $298.46, the median forecast implies a 50.8% upside. This outlook is supported by 14 Buy, 0 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Kambiz Yazdi at BTIG, projecting a 182.4% upside. Conversely, the most conservative target is provided by Laura Chico at Wedbush, suggesting a 68.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PRAX Analyst Ratings
14
Buy
0
Hold
1
Sell
PRAX Price Target Range
Low
$95.00
Average
$450.00
High
$843.00
Current: $298.46
Latest PRAX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PRAX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 12, 2026 | Wedbush | Laura Chico | Underperform | Maintains | $95.00 |
| Dec 29, 2025 | BTIG | Kambiz Yazdi | Buy | Maintains | $843.00 |
| Dec 15, 2025 | Oppenheimer | Jay Olson | Outperform | Maintains | $750.00 |
| Dec 9, 2025 | Jefferies | Andrew Tsai | Buy | Maintains | $450.00 |
| Dec 9, 2025 | Guggenheim | Yatin Suneja | Buy | Maintains | $760.00 |
| Dec 8, 2025 | BTIG | Kambiz Yazdi | Buy | Maintains | $507.00 |
| Dec 8, 2025 | TD Cowen | Ritu Baral | Buy | Maintains | $353.00 |
| Dec 8, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $340.00 |
| Dec 8, 2025 | Needham | Ami Fadia | Buy | Maintains | $315.00 |
| Dec 8, 2025 | Truist Securities | Joon Lee | Buy | Maintains | $500.00 |
| Dec 5, 2025 | Needham | Ami Fadia | Buy | Maintains | $304.00 |
| Dec 5, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $340.00 |
| Dec 5, 2025 | Wedbush | Laura Chico | Underperform | Maintains | $83.00 |
| Dec 1, 2025 | Needham | Ami Fadia | Buy | Reiterates | $250.00 |
| Nov 25, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $258.00 |
| Nov 19, 2025 | BTIG | Kambiz Yazdi | Buy | Initiates | $424.00 |
| Nov 13, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $258.00 |
| Nov 6, 2025 | Wedbush | Laura Chico | Underperform | Maintains | $77.00 |
| Oct 20, 2025 | Wedbush | Daniel Ives | Underperform | Maintains | $73.00 |
| Oct 17, 2025 | Guggenheim | Yatin Suneja | Buy | Maintains | $350.00 |
Praxis Precision Medicines Inc. (PRAX) Competitors
The following stocks are similar to Praxis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Praxis Precision Medicines Inc. (PRAX) Financial Data
Praxis Precision Medicines Inc. has a market capitalization of $8.28B with a P/E ratio of -29.1x. The company generates $7.46M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -3,927.5% and return on equity of -75.2%.
Valuation Metrics
Market Cap
$8.28B
Enterprise Value
$6.63B
P/E Ratio
-29.1x
PEG Ratio
-1.3x
Price/Sales
1,043.8x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-3,927.5%
Net Margin
0.0%
EPS Growth
-100.0%
Financial Health
Cash/Price Ratio
+3.6%
Current Ratio
5.2x
Debt/Equity
0.1x
ROE
-75.2%
ROA
-45.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Praxis Precision Medicines Inc. (PRAX) Business Model
About Praxis Precision Medicines Inc.
What They Do
Develops treatments for central nervous system disorders.
Business Model
The company focuses on developing innovative therapies to address unmet medical needs in CNS disorders. It generates revenue through the commercialization of its drug candidates, which target conditions like epilepsy and psychiatric disorders, leveraging its research in genetics and neurobiology.
Additional Information
Praxis Precision Medicines is positioned as an emerging leader in the biopharmaceutical sector, with a strong commitment to improving patient outcomes and advancing personalized medicine through their diverse pipeline of therapeutic candidates.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
116
CEO
Mr. Marcio Silva De'Souza M.B.A.
Country
United States
IPO Year
2020
Website
praxismedicines.comPraxis Precision Medicines Inc. (PRAX) Latest News & Analysis
Latest News
Quick Summary
Praxis Precision Medicines appointed Jeffrey B. Kindler and Stuart Arbuckle to its board and promoted Megan Sniecinski to COO and Dr. Steven Petrou to President of R&D.
Why It Matters
Leadership changes can signal strategic shifts and influence company direction, impacting investor confidence and stock performance in Praxis Precision Medicines.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6 days ago
Quick Summary
Praxis Precision Medicines granted 434 restricted stock units to three new non-executive employees on January 2, 2026, under its 2024 Inducement Plan, per Nasdaq rules.
Why It Matters
The granting of restricted stock units suggests confidence in attracting talent, which can enhance company performance and drive share value in the long term.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Praxis Precision Medicines (NASDAQ: PRAX) announced a proposed public offering of common stock and pre-funded warrants, with underwriters offered a 30-day option for additional shares.
Why It Matters
Praxis Precision Medicines' public offering signals potential dilution of shares, impacting existing shareholders. It may raise capital for R&D, influencing future growth prospects and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Praxis Precision Medicines (NASDAQ: PRAX) priced a public offering of 2.21 million shares at $260 each, aiming for $575 million in gross proceeds. The offering closes around January 8, 2026.
Why It Matters
Praxis Precision Medicines' $575 million stock offering boosts liquidity for R&D, signaling confidence in growth. It may impact share prices and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Praxis Precision Medicines aims to address the significant demand for effective treatments for movement disorders, indicating potential growth in the healthcare sector.
Why It Matters
Praxis Precision Medicines targets a significant market with unmet treatment needs, suggesting potential for growth and profitability, which can attract investor interest and drive stock performance.
Source: The Motley Fool
Market Sentiment:
Positive
Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday
17 days ago
Quick Summary
Top Wall Street analysts have revised their outlook on several major companies. For detailed analyst rating changes, refer to the analyst ratings page.
Why It Matters
Analyst rating changes can signal shifts in market sentiment, impacting stock prices and investor confidence in those companies. Monitoring these changes is crucial for informed decision-making.
Source: Benzinga
Market Sentiment:
Positive
Frequently Asked Questions About PRAX Stock
What is Praxis Precision Medicines Inc.'s (PRAX) stock forecast for 2026?
Based on our analysis of 19 Wall Street analysts, Praxis Precision Medicines Inc. (PRAX) has a median price target of $450.00. The highest price target is $843.00 and the lowest is $95.00.
Is PRAX stock a good investment in 2026?
According to current analyst ratings, PRAX has 14 Buy ratings, 0 Hold ratings, and 1 Sell ratings. The stock is currently trading at $298.46. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PRAX stock?
Wall Street analysts predict PRAX stock could reach $450.00 in the next 12 months. This represents a 50.8% increase from the current price of $298.46. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Praxis Precision Medicines Inc.'s business model?
The company focuses on developing innovative therapies to address unmet medical needs in CNS disorders. It generates revenue through the commercialization of its drug candidates, which target conditions like epilepsy and psychiatric disorders, leveraging its research in genetics and neurobiology.
What is the highest forecasted price for PRAX Praxis Precision Medicines Inc.?
The highest price target for PRAX is $843.00 from Kambiz Yazdi at BTIG, which represents a 182.4% increase from the current price of $298.46.
What is the lowest forecasted price for PRAX Praxis Precision Medicines Inc.?
The lowest price target for PRAX is $95.00 from Laura Chico at Wedbush, which represents a -68.2% decrease from the current price of $298.46.
What is the overall PRAX consensus from analysts for Praxis Precision Medicines Inc.?
The overall analyst consensus for PRAX is bullish. Out of 19 Wall Street analysts, 14 rate it as Buy, 0 as Hold, and 1 as Sell, with a median price target of $450.00.
How accurate are PRAX stock price projections?
Stock price projections, including those for Praxis Precision Medicines Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 3:25 PM UTC